By Mike Snow
Mike Snow has worked as a journalist in Asia, Africa, South America and Washington, D.C., reporting about international and domestic politics, health, travel and agriculture.
Since its founding in 1965, the International Agency for Research on Cancer (IARC) has doggedly hunted for the causes of one of humanity’s most pernicious and persistent diseases. After IARC’s independent researchers concluded in 2015 that glyphosate, the premier ingredient in Monsanto’s broad-spectrum systemic herbicide and crop desiccant Roundup is “probably carcinogenic,” the hunter became the hunted.
Glyphosate, which has become integral to genetically engineered, industrialized agriculture, is found in products produced by 100 companies in more than 130 countries. Since its 1974 rollout, sales have skyrocketed from 3,200 to 825,000 tons per year, contributing mightily to the to the agro-chem giant’s roughly $16 billion annual revenue stream.
Neither glyphosate nor Monsanto (now Bayer) have been without controversy. The chemical is just the latest in a long line of products that have kept the 117-year-old-company lurching from one crisis to another, deflecting discomforting inquiries to marketers and lobbyists and, when real muscle was required, attorneys and politicians. But because of its star status in Monsanto’s product hierarchy, IARC’s designation of glyphosate as “probably carcinogenic” hit a raw nerve, triggering a cry for all hands on deck. Within hours of its announcement, the agency’s independent scientists found themselves caught in the crosshairs of a sustained, choreographed campaign aimed not only at discrediting them, but at taking them down. Continue Reading →